← Leaderboards
Sani Haider Kizilbash
Mayo Clinic Rochester
$882,009
Attributed
$882,009
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $297.5K · FY2021–24$500K$375K$250K$125K$0
'21
'22
'23
'24
Funding mix
By agency
FDA$882,009 · 1
By mechanism
R01$882,009 · 1
Top collaborators
No co-investigators on record.
Grant awards (3)
Phase I study to evaluate safety, tolerability, pharmacokinetics and anti-tumor activity of WSD0922-FU$297,510
R01 · FY2024 · FD · contact PI
Phase I study to evaluate safety, tolerability, pharmacokinetics and anti-tumor activity of WSD0922-FU$297,510
R01 · FY2022 · FD · contact PI
Phase I study to evaluate safety, tolerability, pharmacokinetics and anti-tumor activity of WSD0922-FU$286,989
R01 · FY2021 · FD · contact PI